Citations (20)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Lu Chai, Zhe Li, Ting Wang, Ran Wang, Kanokwan Pinyopornpanish, Gang Cheng & Xingshun Qi. (2023) Efficacy and safety of tolvaptan in cirrhotic patients: a systematic review and meta-analysis of randomized controlled trials. Expert Review of Gastroenterology & Hepatology 17:10, pages 1041-1051.
Read now
Read now
Articles from other publishers (19)
Dominique Thabut, Charlotte Bouzbib, Lucy Meunier, Manon Haas, Nicolas Weiss, Alexandre Louvet, Francois Imbert‐Bismut, Fanny Mochel, Yann Nadjar, Antoine Santiago, Thierry Thevenot, Véronique Duhalde, Frédéric Oberti, Claire Francoz, Audrey Coilly, Marie‐Noelle Hilleret, Pascal Lebray, Amélie Liou‐Schischmanoff, Louise Barbier, Christophe Duvoux, Georges‐Philippe Pageaux, Michael Bismuth, Damien Galanaud, Thomas De Broucker, Jean‐François Cadranel, Vincent Leroy, Vincent Di Martino, Dominique Larrey, Christophe Camus, Olivier Scatton, Victor De Ledinghen, Ariane Mallat, Marika Rudler & Christophe Bureau. (2023) Diagnosis and management of hepatic encephalopathy: The French recommendations. Liver International 43:4, pages 750-762.
Crossref
Crossref
Kazuya Okushin, Ryosuke Tateishi, Arata Takahashi, Koji Uchino, Ryo Nakagomi, Takuma Nakatsuka, Tatsuya Minami, Masaya Sato, Mitsuhiro Fujishiro, Kiyoshi Hasegawa, Yuichiro Eguchi, Tatsuya Kanto, Shoji Kubo, Hitoshi Yoshiji, Hiroaki Miyata, Namiki Izumi, Masatoshi Kudo & Kazuhiko Koike. (2022) Current status of primary liver cancer and decompensated cirrhosis in Japan: launch of a nationwide registry for advanced liver diseases (REAL). Journal of Gastroenterology 57:8, pages 587-597.
Crossref
Crossref
Michitaka Imai, Toru Ishikawa, Yuichi Kojima, Motoi Azumi, Yujiro Nozawa, Tomoe Sano, Akito Iwanaga, Terasu Honma & Toshiaki Yoshida. (2020) Prediction factors of tolvaptan effectiveness in patients with refractory ascites complicated with hepatocellular carcinoma. European Journal of Gastroenterology & Hepatology 33:1S, pages e161-e166.
Crossref
Crossref
Takuya Adachi, Yasuto Takeuchi, Akinobu Takaki, Atsushi Oyama, Nozomu Wada, Hideki Onishi, Hidenori Shiraha & Hiroyuki Okada. (2021) Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan. International Journal of Molecular Sciences 22:11, pages 5582.
Crossref
Crossref
Y Suzuki, A Naganuma, T Hoshino, T Hatanaka, T Ueno, M Namikawa, D Takizawa, H Arai, H Suzuki, H Takagi, H Tojima, Y Yamazaki, K Sato, S Kakizaki & T Uraoka. (2021) Tolvaptan reduces the required amount of albumin infusion in patients with decompensated cirrhosis with uncontrolled ascites : a multicenter retrospective propensity score-matched cohort study. Acta Gastro Enterologica Belgica 84:1, pages 57-63.
Crossref
Crossref
Jieting Tang, Yongfeng Wang, Tao Han, Qing Mao, Jun Cheng, Huiguo Ding, Jia Shang, Qin Zhang, Junqi Niu, Feng Ji, Chengwei Chen, Jidong Jia, Xiangjun Jiang, Nonghua Lv, Yueqiu Gao, Zhenghua Wang, Zhong Wei, Yingxuan Chen, Minde Zeng & Yimin Mao. (2020) Tolvaptan therapy of Chinese cirrhotic patients with ascites after insufficient diuretic routine medication responses: a phase III clinical trial. BMC Gastroenterology 20:1.
Crossref
Crossref
Shinichi Morita, Shunsuke Sugawara, Takeshi Suda, Didik Prasetyo, Yuka Kobayashi, Takahiro Hoshi, Satoshi Abe, Kazuyoshi Yagi & Shuji Terai. (2020) Stent Placement for Malignant Inferior Vena Cava Syndrome in a Patient with Recurrent Colon Cancer. Internal Medicine 59:22, pages 2885-2890.
Crossref
Crossref
Mohamed El‐Shabrawy, Amal Mishriki, Hisham Attia, Basma Emad Aboulhoda, Mohamed Emam & Hanaa Wanas. (2020) Protective effect of tolvaptan against cyclophosphamide‐induced nephrotoxicity in rat models. Pharmacology Research & Perspectives 8:5.
Crossref
Crossref
Shankar Lanke & Susan E. Shoaf. (2019) Population Pharmacokinetic Analyses and Model Validation of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease. The Journal of Clinical Pharmacology 59:5, pages 763-770.
Crossref
Crossref
Makoto Segawa & Isao Sakaida. 2019. Clinical Investigation of Portal Hypertension. Clinical Investigation of Portal Hypertension
501
508
.
Takuro HISANAGA, Takahiro YAMASAKI, Masaki MAEDA, Takuya IWAMOTO, Issei SAEKI, Toshihiko MATSUMOTO, Isao HIDAKA, Yoshio MARUMOTO, Tsuyoshi ISHIKAWA, Taro TAKAMI & Isao SAKAIDA. (2017) Effectiveness of Early Intervention by Specialized Institutions for Liver Cirrhosis Patients肝硬変患者に対する肝疾患専門医療機関の早期介入の有効性. Yamaguchi Medical Journal 66:3, pages 163-168.
Crossref
Crossref
Yanqiong Zhang, Chen Yan, Yuting Li, Xia Mao, Weiwei Tao, Yuping Tang, Ya Lin, Qiuyan Guo, Jingao Duan & Na Lin. (2017) Therapeutic effects of Euphorbia Pekinensis and Glycyrrhiza glabra on Hepatocellular Carcinoma Ascites Partially Via Regulating the Frk-Arhgdib-Inpp5d-Avpr2-Aqp4 Signal Axis. Scientific Reports 7:1.
Crossref
Crossref
Isao Sakaida, Shuji Terai, Koji Nakajima, Yoshiyuki Shibasaki, Sayaka Tachikawa & Hidetsugu Tsubouchi. (2016) Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis. Journal of Gastroenterology 52:2, pages 229-236.
Crossref
Crossref
Y. Lu, J. R. Slizgi, K. R. Brouwer, R. L. St. Claire, K. M. Freeman, M. Pan, W. J. Brock & K. L. R. Brouwer. (2016) Hepatocellular Disposition and Transporter Interactions with Tolvaptan and Metabolites in Sandwich-Cultured Human Hepatocytes. Drug Metabolism and Disposition 44:6, pages 867-870.
Crossref
Crossref
Jia-Long Fang, Yuanfeng Wu, Gonçalo Gamboa da Costa, Si Chen, Priyanka Chitranshi & Frederick A. Beland. (2016) Human Sulfotransferases Enhance the Cytotoxicity of Tolvaptan. Toxicological Sciences 150:1, pages 27-39.
Crossref
Crossref
Takuya Iwamoto, Masaki Maeda, Takuro Hisanaga, Issei Saeki, Koichi Fujisawa, Toshihiko Matsumoto, Isao Hidaka, Tsuyoshi Ishikawa, Taro Takami & Isao Sakaida. (2016) Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis. Internal Medicine 55:20, pages 2911-2916.
Crossref
Crossref
Ya Lin, Yanqiong Zhang, Erxin Shang, Wenfang Lai, Hongwei Zhu, Yuhua Fang, Qingxia Qin, Haiyu Zhao & Na Lin. (2016)
Effect of
Glycyrrhiza
on the Diuretic Function of
Euphorbia kansui
: An Ascites Mouse Model
. Evidence-Based Complementary and Alternative Medicine 2016, pages 1-13.
Crossref
Crossref
Jason R. Slizgi, Yang Lu, Kenneth R. Brouwer, Robert L. St. Claire, Kimberly M. Freeman, Maxwell Pan, William J. Brock & Kim L. R. Brouwer. (2016) Inhibition of Human Hepatic Bile Acid Transporters by Tolvaptan and Metabolites: Contributing Factors to Drug-Induced Liver Injury?. Toxicological Sciences 149:1, pages 237-250.
Crossref
Crossref
Yuichi Shimomura, William J. Brock, Yuko Ito & Katsumi Morishita. (2015) Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat. International Journal of Toxicology 34:6, pages 479-490.
Crossref
Crossref